CORDIS
EU research results

CORDIS

English EN

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Objective

Parkinson Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There is an unmet clinical need to treat Parkinson disease with mild cognitive impairment (PD-MCI). There is ample evidence from epidemiological studies as well as (pre)clinical research that Nicotinic receptors are involved in PD and cognition. Recently a clinical trial suggested that selective α7 nicotinic receptor agonist improved cognition in PD patients, as a secondary outcome measure. Hence, the main goal of PD-MIND is to show the potential of the Astrazeneca nicotinic α7 agonist AZD0328 in a randomized, placebo-controlled, international multicentre, cross-over study on cognition in people diagnosed with PD-MCI. We will assess the Attention Intensity Index composite score from the CogTrackTM system as primary outcome measure and other clinical aspects (cognition, motor symptoms) as secondary outcomes. In addition, blood, CSF and imaging biomarkers will be assessed as potential predictors of response, and as marker of target involvement. Patients (Public and Patient Involvement) and other stakeholders will be engaged from the start to allow integration of end-user perspectives in the design and execution of the project. PD-MIND will put considerably effort to disseminate and exploit clinical outcome data and biomarker results, and to sustain the partnership for subsequent phase 3 clinical studies. PD-MIND consortium consist of world-leading PD-MCI experts in the area of clinical trials, clinical coordination, project management, data management and analysis, and biomarkers. As such the consortium is well positioned to execute the proposed work and complement the EFPIA members.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KING'S COLLEGE LONDON

Address

Strand
Wc2r 2ls London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 524 820

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

STICHTING LYGATURE

Netherlands

EU Contribution

€ 100 937,25

THE UNIVERSITY OF EXETER

United Kingdom

EU Contribution

€ 184 398,75

HELSE STAVANGER HF

Norway

EU Contribution

€ 16 417

UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA

Italy

EU Contribution

€ 58 125

TECHNISCHE UNIVERSITAET DRESDEN

Germany

EU Contribution

€ 58 125

NORGES PARKINSONFORBUND

Norway

EU Contribution

€ 16 250

Masarykova univerzita

Czechia

EU Contribution

€ 40 625

ASTRAZENECA AB

Sweden

PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG

United Kingdom

Project information

Grant agreement ID: 820880

Status

Ongoing project

  • Start date

    1 May 2019

  • End date

    30 April 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 2 131 609,01

  • EU contribution

    € 999 698

Coordinated by:

KING'S COLLEGE LONDON

United Kingdom